Cancer Patient Faces $9,700 Bill After Drug Funding Ends

Robyn Crawford, a Calgary resident diagnosed with metastatic breast cancer, is requesting continued provincial funding for pembrolizumab, also known as Keytruda. This immunotherapy has reportedly shrunk her tumors and maintained stability for approximately one year. Crawford now faces an out-of-pocket cost of $9,700 every three weeks for the drug, as she has reached Alberta's maximum treatment limit.

Alberta's cancer drug funding criteria specify a two-year maximum for pembrolizumab in eligible patients with metastatic triple-negative breast cancer, a limit that aligns with Canadian reimbursement recommendations. Cancer Care Alberta stated that this two-year timeframe reflects available clinical evidence on safety and effectiveness. They noted that fixed limits are standard in Canadian public drug programs for immune checkpoint inhibitors, with limited evidence supporting treatment beyond 24 months.

Despite her cancer remaining stable, Crawford, who is unable to work due to side effects like fatigue and brain fog, expressed distress over the potential cessation of treatment. Health policy experts highlight the challenge of balancing finite budgets with individual patient needs, suggesting that a lack of study does not always mean a treatment won't work. Patient advocacy groups emphasize that treatment decisions should be guided by oncologists, not affordability, and that funding policies should accommodate recommended therapies.

Advocates suggest that provinces often have exceptional-access pathways for drug coverage outside standard criteria, though these are not guaranteed. Crawford reported receiving short notice about her funding ending, leading to concerns about exploring alternative treatments or insurance. She hopes her public appeal will prompt flexibility and a review of policies affecting patients in similar situations, aiming to secure continued access to her vital medication.